viernes, 9 de noviembre de 2018

FDA approves new drug for maintenance treatment of adult patients with chronic obstructive pulmonary disease (COPD) - Drug Information Update


Today, the U.S. Food and Drug Administration (FDA) approved 
Yupelri (revefenacin) Inhalation Solution for the maintenance treatment 
of patients with chronic obstructive pulmonary disease (COPD). 
Revefenacin is a long-acting muscarinic antagonist (LAMA), which is a
class of medicines that improve lung function in patients with COPD. 
Revefenacin is an inhalation solution that is administered once daily via 
a standard jet nebulizer.  

As with other inhaled medicines, revefenacin can cause paradoxical 
bronchospasm (wheezing). If paradoxical bronchospasm occurs, patients 
should discontinue use. Patients should also be alert for signs and 
symptoms of acute narrow-angle glaucoma (e.g., eye pain or discomfort, 
blurred vision, visual changes). Patients should consult a healthcare 
professional immediately if any of these signs or symptoms develop.

The most common adverse reactions include cough, nasopharyngitis 
(swelling of the nasal passages and the back of the throat), upper 
respiratory tract infection, headache, and back pain. Health care 
professionals should avoid administering revefenacin with other 
anticholinergic-containing drugs. The agency does not recommend 
administering revefenacin at the same time as OATP1B1 and OATP1B3 
inhibitors (e.g. rifampicin, cyclosporine, etc.), as it may lead to an 
increase in exposure of the active metabolite. 

For more information, please visit: 
Yupelri (revefenacin) Inhalation Solution.

No hay comentarios:

Publicar un comentario